BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Hires IR Firm Torrey Hills Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced its engagement of Rancho Santa Fe, California-based investor relations firm San Diego Torrey Hills Capital, Inc. (“Torrey Hills Capital”) to deliver market awareness and investor relations services to IMEXF, subject to acceptance by the Canadian Securities Exchange (“CSE”). The move enables the company to cultivate an informed investor audience in both the U.S. and Canadian marketplaces. The company has engaged the firm at a rate of US$7,000 per month. Following the initial term of three months, the agreement will be automatically increased, subject to a 30-day termination notice by either party. Additionally, IMEXF will grant Torrey Hills Capital 100,000 incentive stock options exercisable at a price of C$0.62 per share for a period of three years.

To view the full press releases, visit https://ibn.fm/DAGEl

Imagin Medical Inc.

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal and help reduce recurrence rates. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S. and the third most common cancer in men. Worldwide, over 380,000 new cases are diagnosed each year. With treatment costs of $4 billion per year in the U.S. alone, bladder cancer is the most expensive cancer to treat during the lifetime of a patient, with approximately 60% of the costs attributable to recurrence. Over 80,000 new cases each year and almost 600,000 patients in the U.S. living in fear of their bladder cancer returning represent a large market that can benefit from the company’s i/Blue Imaging technology. Learn more at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork